Tubingen, Germany
CureVac, a biotech innovator founded in 2000 and based in Germany, is at the forefront of the mRNA technology revolution. Known for their slogan, "We fight for human health - we are the RNA people," CureVac has been instrumental in the advancement and optimization of mRNA technologies over the past two decades. Their contributions have been pivotal in developing mRNA vaccines, most notably against COVID-19.
With operations in Germany, the Netherlands, Belgium, Switzerland, and the U.S., the company is expanding the applications of mRNA beyond vaccines, exploring therapeutic areas with significant unmet needs such as personalized cancer vaccines and treatments that empower the body to produce its own therapeutic proteins.
Their recent acquisition investment of $1.25B by BioNTech on 01 June 2025 underscores growing confidence in CureVac's robust pipeline and innovative approach, reinforcing their position as a key player in the biotech industry.
Arcturus Therapeutics